LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization ... Outlook Therapeutics’ commercialization strategy, ...
Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused ...
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated ...
Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel ...
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, ...
Mr. Iwicki stated, “I am proud of the work we have done at KALA utilizing our MSC-S platform, and I am very excited about the potential of our lead product candidate, KPI-012 for the treatment of PCED ...
furthers its VerifyUTM commercialization strategy that was announced today by the National Football League Alumni (NFLA). The Web 3.0 project is with the historic and World-renowned NFLA in a 3 ...
Investing News Network on MSN3d
What is In-Licensing?When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...
Hosted on MSN15d
Molson Coors Beverage Company Announces Strategic Partnership With Fever-Tree in U.S.Starting February 1, 2025, Molson Coors will assume exclusive commercialization rights to Fever-Tree’s award-winning lineup of tonics, ginger beers, cocktail mixers and more in the U.S. and will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback